RVMD - Revolution Medicines Inc Company Long-Term Liabilities

Public company logo of Revolution Medicines Inc (RVMD)

Changes in the long-term liabilities of Revolution Medicines (RVMD) reflect borrowing dynamics, with the indicator reaching the level of 1.17. A lack of sales due to the research stage nullifies revenue and renders cash flows unpredictable. Business prospects are tied to regulatory approvals and external financing. Currently, Revolution Medicines is focusing on completing final trials of its targeted oncology drugs.

revmed.com (RVMD) Company Long-Term Debt: for the period 07/04/2022 - 11/01/2026

RevMed (RVMD) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price revmed.com|RVMD - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Revolution Medicines|RVMD - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Revolution Medicines|RVMD - Company Book Value|Market Value to Book Value revmed.com|RVMD - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Revolution Medicines|RVMD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Revolution Medicines Corp|RVMD - Company Total Debt|Debts to Book Capitalization Revolution Medicines|RVMD - Company Long-Term Debt|Company Short-Term Loans and Borrowings Revolution Medicines|Immediate Liquidity revmed.com
- earnings and market multiples details:
RVMD - Company Net Income
Fundamental company valuation:RVMD (revmed.com)
Brand item of Revolution Medicines

Fundamental asset selection requires an analysis of the capital structure to assess the issuer's resilience to long-term financial risks. This indicator measures the volume of liabilities with a maturity of more than one year, which is critical for Revolution Medicines (RVMD) when financing the costly deployment of robotic oncology laboratories, and this trend is clearly illustrated through the assessment of the issuer's long-term liabilities.

Competitors of Revolution Medicines (RVMD)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Ascentage Pharma Group International (AAPG) - Company Long-Term Liabilities|CGON: Company Long-Term Debts|Long-Term Debt UroGen Pharma Corp (URGN)|Company Long-Term Debt Bicara Therapeutics Inc.|PSNL: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities ERAS (Erasca)|DCTH (Delcath Systems Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts YMAB (YmAbs)|AURA - Company Long-Term Liabilities|CADL: Company Long-Term Liabilities|ARAY - Company Long-Term Debts|sellaslifesciences.com (SLS) - Company Long-Term Debt|Actuate Therapeutics Inc. - Company Long-Term Loans and Borrowings|CTOR (Citius Oncology, Inc) - Company Long-Term Debts|Long-Term Debt TuHURA HURA|Company Long-Term Debt Protara Therapeutics (TARA)|FATE (fatetherapeutics.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Long-Term Debt|CSBR: Company Long-Term Liabilities|XBIT: Company Long-Term Debt|cel-sci.com (CVM) - Company Long-Term Debt|Long-Term Debt ostherapies.com (OSTX)|Company Long-Term Debt Radiopharm Theranostics Limited|Company Long-Term Debt ARTV|Company Long-Term Liabilities ANL (Adlai Nortye Ltd.)|Company Long-Term Debts Veru Corporation (VERU)|Tempest Therapeutics - Company Long-Term Liabilities|Amount of Long-Term Liabilities XLO (Xilio Therapeutics Inc)|Enochian BioSciences - Company Long-Term Debts|Long-Term Debt Volume Mural Oncology plc MURA|kairospharma.com (KAPA) - Company Long-Term Debt|Long-Term Debt OnKure Therapeutics (OKUR)|Company Long-Term Debt CytoMed Therapeutics Ltd|Company Long-Term Indebtedness CRIS (Curis Corp)|Company Long-Term Liabilities APLM (Apollomics, Inc.)|THAR (Tharimmune Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Advanced Biomed ADVB|GNPX - Company Long-Term Liabilities|Calidi Bio - Company Long-Term Debts|Long-Term Debt Sunshine Biopharma Inc.|XBIO: Company Long-Term Debts|Company Long-Term Indebtedness SLRX|PPBT (Purple Biotech Corp) - Company Long-Term Debts|AON (AONC) - Long-Term Debt Volume|Company Long-Term Debts BGNE|Company Long-Term Liabilities checkpointtx.com CKPT|Company Long-Term Debts ELEV (Elevation Oncology, Inc.)|Long-Term Debt Volume iCAD Inc. (ICAD)|IKNA - Company Long-Term Debt|NTBL (Notable Labs Corp) - Company Long-Term Indebtedness|VIRX: Company Long-Term Debts|Long-Term Debt morphosys.com (MOR)|Company Long-Term Debt NAYA Biosciences Inc.|Ascentage Pharma Group International (AAPGV) - Long-Term Debt Volume